Developer docs
API playgroundTry for free, no card

Search company profiles

Sinopia Biosciences

Full company profile

uuid0000sxo

Namestring
Sinopia Biosciences
Legal namestring
Sinopia Biosciences, Inc.
Websiteurl
sinopiabio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Sinopia Biosciences is a privately held, pre-clinical biotechnology company founded in 2014 and headquartered at JLABS San Diego that has built the LEADS® (LEarn And DiScover) platform, a drug discovery engine combining high-throughput metabolomics, multi-omics data, proprietary deep learning foundation models, and network analyses to identify novel therapeutic targets and compounds. The platform is anchored on what Sinopia describes as the largest metabolomics dataset characterizing a small-molecule library and integrates metabolomics, genomics, and proteomics to predict therapeutic response and disease biology with greater sensitivity than upstream-biomolecule-only approaches. The company's internal pipeline is led by SB-0110, a first-in-class positive allosteric modulator of PKA-II for Parkinson's disease and levodopa-induced dyskinesia, which is advancing into Phase 1 clinical trials, with a second program in oral mucositis funded by NIDCR and a third oncology effort funded by NCI.

Sinopia generates revenue through non-dilutive grant funding from multiple NIH institutes (NIGMS, NINDS, NIDCR, NHLBI, NCI) and the Michael J. Fox Foundation, with cumulative NIH and MJFF funding exceeding $14M and an additional Ono Pharmaceutical target-discovery collaboration announced in March 2026 adding research funding, upfront payments, and milestone eligibility. The company has not yet commercialized any product, has no recurring software or services revenue, and operates with a headcount of 1–10 employees. Its IP estate includes 14 issued or allowed patents worldwide, including a composition-of-matter patent for SB-0110 issued in the US in January 2026 and parallel grants in Japan, China, Taiwan, and Mexico.

The leadership team combines academic systems biology pedigree with operational drug-development experience: co-founder Bernhard Palsson (700+ publications, 40+ patents, NAE member), CTO Aarash Bordbar (PI on $14M in grants, 13 patents), and CEO Iman Famili (16 patents, prior roles at Intrexon, Genomatica, GT Life Sciences). The board includes Executive Chair Arthur Suckow, who previously founded DTx Pharma and sold it to Novartis for $1B, and Abhay Joshi, former COO of Revance Therapeutics. The company has been an NVIDIA Inception member since 2019 and reports no venture capital or private equity funding disclosed to date.

Short descriptiontext

Sinopia Biosciences is a pre-clinical biotech that uses its LEADS® platform — combining metabolomics, multi-omics data, and proprietary deep learning foundation models — to discover first-in-class therapeutics, with lead candidate SB-0110 entering Phase 1 trials for Parkinson's disease and additional programs in oral mucositis and oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, multi-omics analytics, machine learning therapeutics, small molecule discovery, biopharmaceutical R&D
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Grant Funding (NIH)
TypeSubscription Recurring
Description

Sinopia Biosciences generates non-dilutive funding through multiple SBIR and other grants from the National Institutes of Health and its institutes (NIGMS, NINDS, NIDCR, NCI, NHLBI). These grants fund platform development and specific therapeutic programs.

sinopiabio.com
2Strategic Partnerships and Collaborations
TypeLicensing Royalties
Description

Sinopia receives research funding, upfront payments, and is eligible for future milestones through partnerships with pharmaceutical companies such as Ono Pharmaceutical for target discovery collaborations.

sinopiabio.com
3Future Therapeutic Development
TypeOne Time License
Description

The company is advancing multiple first-in-class programs with high unmet need toward clinical development, with the lead program SB-0110 for Parkinson's disease progressing toward IND-enabling studies and clinical trials.

sinopiabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1LEADS®
Description

LEarn And DiScover - Proprietary drug discovery platform combining high-throughput omics data, AI/machine learning, and network analyses for data-driven drug discovery.

sinopiabio.com
Core offering1 text field

Sinopia Biosciences operates a proprietary drug-discovery platform called LEADS (LEarn And DiScover) that integrates high-throughput metabolomics data, AI/machine-learning foundation models engineered for omics, network analyses, and disease models to identify novel therapeutic targets and advance small-molecule drug candidates. Its most advanced program, SB-0110, is in clinical development for Parkinson's disease, with additional research programs spanning oral mucositis, oncology, rare blood disorders (platelet production), and rare metabolic diseases. The company monetizes this capability primarily through grant-funded research and milestone-bearing collaborations with biopharmaceutical partners such as Ono Pharmaceutical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Identified novel targets for multiple indications that were successfully validated in vivo
+3 more records
Product overview1 text field

Sinopia Biosciences operates as a single-platform biotechnology company centered on its proprietary LEADS® (LEarn And DiScover) drug discovery platform. The company leverages this AI/ML-driven omics platform to discover first-in-class therapeutics, with its lead development candidate SB-0110 for Parkinson's disease. The LEADS platform integrates high-throughput metabolomics data, deep learning foundation models, and network biology analyses to identify novel therapeutic targets and compounds. All therapeutic programs are discovered and developed internally through this platform.

Product and service3 records
1LEADS Drug Discovery Platform
CategoryDrug Discovery Platform
Description

Proprietary AI/omics drug-discovery platform integrating high-throughput metabolomics, machine-learning foundation models built for omics data, network analyses, and disease models to identify novel therapeutic targets and small-molecule candidates; serves as the company's primary internal discovery engine and the basis of its partnership/collaboration offerings.

2SB-0110 — Parkinson's disease lead program
CategoryTherapeutic Program (Neurology / Parkinson's disease)
Description

Lead small-molecule clinical-stage therapeutic candidate of Sinopia Biosciences, in development for Parkinson's disease; serves as the flagship asset validating the LEADS platform and is the focus of ongoing clinical and translational activity.

3Target-Discovery Partnership / Collaboration Program
CategoryDrug Discovery Services / Partnership Offering
Description

B2B service offering through which Sinopia applies the LEADS platform to identify and advance novel therapeutic targets and small-molecule candidates for biopharmaceutical partners under milestone-bearing research collaborations; demonstrated by the Ono Pharmaceutical target-discovery collaboration.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Ono Pharmaceutical Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Sinopia Biosciences announced a target discovery collaboration with Ono Pharmaceutical focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Sinopia will apply its proprietary metabolomics-driven discovery platform (LEADS) to identify and validate novel therapeutic targets. Ono Pharmaceutical may advance identified targets toward development of new medicines. Sinopia will receive research funding, an upfront payment, and is eligible for future milestones.

sinopiabio.com
2Omix Technologies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-01
Description

NIGMS Phase I SBIR awarded to Sinopia Biosciences and Omix Technologies to develop a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery. The collaboration combines Sinopia's computational analysis expertise with Omix's ability to generate metabolomics data with unprecedented throughput, accuracy, and precision for applications in drug discovery, drug repurposing, and drug safety.

sinopiabio.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-08-24
Description

Multi-center collaboration for NHLBI Phase II SBIR on improving red blood cell transfusion through systems biology. The San Diego Blood Bank collaborated on testing novel additives to better preserve red blood cells for transfusion.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Computational chemistry and materials science platform with a broader drug discovery offering including software, services, and internal pipeline. Larger and more diversified than Sinopia, but overlapping in the AI/ML-meets-pharma-discovery space.

TypeDirect peer
Description

AI/ML-driven biotech identifying drug targets from human aging biology data. Comparable approach to Sinopia in using proprietary omics datasets and machine learning for target identification and compound prioritization.

TypeDirect peer
Description

AI-native pharma combining precision design with automated experimentation to advance small molecule drug candidates. Comparable to Sinopia in marrying AI/ML with small-molecule discovery, though Exscientia has multiple clinical-stage assets and a much larger capital base.

TypeDirect peer
Description

AI-driven small molecule drug design using structure-based deep learning. Comparable to Sinopia's LEADS platform as an AI/ML drug discovery partner for pharma, with similar partnership-driven GTM motions.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutic targets. Directly comparable to Sinopia's LEADS platform in approach (data + ML for target ID) but at significantly larger scale and with clinical-stage assets.

TypeDirect peer
Description

Machine learning-driven drug discovery platform integrating high-throughput biology and predictive models for therapeutic discovery. Closely aligned with Sinopia's LEADS philosophy of using ML on rich biological data to uncover novel targets.

TypeDirect peer
Description

AI-driven precision oncology company using machine learning and multi-omics to identify and advance targeted therapies. Relevant given Sinopia's NCI-funded oncology work on cancer therapy resistance signatures.

TypeEmerging player
Description

AI for biomedical research applying federated learning to multi-omics and clinical data for drug discovery and diagnostics. Comparable in the AI/omics-driven drug discovery space, particularly relevant to Sinopia's multi-omics integration approach.

TypeOthers
Description

Specialty metabolomics services provider enabling biomarker discovery and multi-omics research. Adjacent to Sinopia — supplies the metabolomics data infrastructure that LEADS builds upon, and a potential data-generation partner.

TypeDirect peer
Description

AI/ML platform applying machine learning to human omics data for neuroscience drug discovery. Particularly relevant given Sinopia's focus on Parkinson's disease and the shared approach of using omics-derived insights to identify CNS targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sinopia Biosciences

Drug Discovery Servicessinopiabio.com

Sinopia Biosciences is a pre-clinical biotech that uses its LEADS® platform — combining metabolomics, multi-omics data, and proprietary deep learning foundation models — to discover first-in-class therapeutics, with lead candidate SB-0110 entering Phase 1 trials for Parkinson's disease and additional programs in oral mucositis and oncology.

What Sinopia Biosciences does

Sinopia Biosciences is a privately held, pre-clinical biotechnology company founded in 2014 and headquartered at JLABS San Diego that has built the LEADS® (LEarn And DiScover) platform, a drug discovery engine combining high-throughput metabolomics, multi-omics data, proprietary deep learning foundation models, and network analyses to identify novel therapeutic targets and compounds. The platform is anchored on what Sinopia describes as the largest metabolomics dataset characterizing a small-molecule library and integrates metabolomics, genomics, and proteomics to predict therapeutic response and disease biology with greater sensitivity than upstream-biomolecule-only approaches. The company's internal pipeline is led by SB-0110, a first-in-class positive allosteric modulator of PKA-II for Parkinson's disease and levodopa-induced dyskinesia, which is advancing into Phase 1 clinical trials, with a second program in oral mucositis funded by NIDCR and a third oncology effort funded by NCI.

Sinopia generates revenue through non-dilutive grant funding from multiple NIH institutes (NIGMS, NINDS, NIDCR, NHLBI, NCI) and the Michael J. Fox Foundation, with cumulative NIH and MJFF funding exceeding $14M and an additional Ono Pharmaceutical target-discovery collaboration announced in March 2026 adding research funding, upfront payments, and milestone eligibility. The company has not yet commercialized any product, has no recurring software or services revenue, and operates with a headcount of 1–10 employees. Its IP estate includes 14 issued or allowed patents worldwide, including a composition-of-matter patent for SB-0110 issued in the US in January 2026 and parallel grants in Japan, China, Taiwan, and Mexico.

The leadership team combines academic systems biology pedigree with operational drug-development experience: co-founder Bernhard Palsson (700+ publications, 40+ patents, NAE member), CTO Aarash Bordbar (PI on $14M in grants, 13 patents), and CEO Iman Famili (16 patents, prior roles at Intrexon, Genomatica, GT Life Sciences). The board includes Executive Chair Arthur Suckow, who previously founded DTx Pharma and sold it to Novartis for $1B, and Abhay Joshi, former COO of Revance Therapeutics. The company has been an NVIDIA Inception member since 2019 and reports no venture capital or private equity funding disclosed to date.

Sinopia Biosciences firmographics

Firmographics
Name
Sinopia Biosciences
Legal name
Sinopia Biosciences, Inc.
Website
https://sinopiabio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Sinopia Biosciences is a pre-clinical biotech that uses its LEADS® platform — combining metabolomics, multi-omics data, and proprietary deep learning foundation models — to discover first-in-class therapeutics, with lead candidate SB-0110 entering Phase 1 trials for Parkinson's disease and additional programs in oral mucositis and oncology.
Ownership category
akta.pro rank

Sinopia Biosciences industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery platform
  • Multi-omics analytics
  • Machine learning therapeutics
  • Small molecule discovery
  • Biopharmaceutical R&D

Where Sinopia Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sinopia Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Grant Funding (NIH): Sinopia Biosciences generates non-dilutive funding through multiple SBIR and other grants from the National Institutes of Health and its institutes (NIGMS, NINDS, NIDCR, NCI, NHLBI). These grants fund platform development and specific therapeutic programs.
  2. Strategic Partnerships and Collaborations: Sinopia receives research funding, upfront payments, and is eligible for future milestones through partnerships with pharmaceutical companies such as Ono Pharmaceutical for target discovery collaborations.
  3. Future Therapeutic Development: The company is advancing multiple first-in-class programs with high unmet need toward clinical development, with the lead program SB-0110 for Parkinson's disease progressing toward IND-enabling studies and clinical trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Sinopia Biosciences product offering

Product offering

Core offering

Sinopia Biosciences operates a proprietary drug-discovery platform called LEADS (LEarn And DiScover) that integrates high-throughput metabolomics data, AI/machine-learning foundation models engineered for omics, network analyses, and disease models to identify novel therapeutic targets and advance small-molecule drug candidates. Its most advanced program, SB-0110, is in clinical development for Parkinson's disease, with additional research programs spanning oral mucositis, oncology, rare blood disorders (platelet production), and rare metabolic diseases. The company monetizes this capability primarily through grant-funded research and milestone-bearing collaborations with biopharmaceutical partners such as Ono Pharmaceutical.

Product overview

Sinopia Biosciences operates as a single-platform biotechnology company centered on its proprietary LEADS® (LEarn And DiScover) drug discovery platform. The company leverages this AI/ML-driven omics platform to discover first-in-class therapeutics, with its lead development candidate SB-0110 for Parkinson's disease. The LEADS platform integrates high-throughput metabolomics data, deep learning foundation models, and network biology analyses to identify novel therapeutic targets and compounds. All therapeutic programs are discovered and developed internally through this platform.

Differentiator

Problem solved

Functional benefit

Brands

  • LEADS®: LEarn And DiScover - Proprietary drug discovery platform combining high-throughput omics data, AI/machine learning, and network analyses for data-driven drug discovery.

Products and services

  • LEADS Drug Discovery Platform Proprietary AI/omics drug-discovery platform integrating high-throughput metabolomics, machine-learning foundation models built for omics data, network analyses, and disease models to identify novel therapeutic targets and small-molecule candidates; serves as the company's primary internal discovery engine and the basis of its partnership/collaboration offerings.
  • SB-0110 — Parkinson's disease lead program Lead small-molecule clinical-stage therapeutic candidate of Sinopia Biosciences, in development for Parkinson's disease; serves as the flagship asset validating the LEADS platform and is the focus of ongoing clinical and translational activity.
  • Target-Discovery Partnership / Collaboration Program B2B service offering through which Sinopia applies the LEADS platform to identify and advance novel therapeutic targets and small-molecule candidates for biopharmaceutical partners under milestone-bearing research collaborations; demonstrated by the Ono Pharmaceutical target-discovery collaboration.

Quantifiable outcome

  • Identified novel targets for multiple indications that were successfully validated in vivo
  • +3 more outcomes

Companies that use Sinopia Biosciences

Customer profile

Segments6 records

Ideal customer profiles3 records

Sinopia Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Sinopia Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Ono Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 3 March 2026Sinopia Biosciences announced a target discovery collaboration with Ono Pharmaceutical focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Sinopia will apply its proprietary metabolomics-driven discovery platform (LEADS) to identify and validate novel therapeutic targets. Ono Pharmaceutical may advance identified targets toward development of new medicines. Sinopia will receive research funding, an upfront payment, and is eligible for future milestones.
  • Omix TechnologiescoreStrategic or Co-development Partner · 1 October 2018NIGMS Phase I SBIR awarded to Sinopia Biosciences and Omix Technologies to develop a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery. The collaboration combines Sinopia's computational analysis expertise with Omix's ability to generate metabolomics data with unprecedented throughput, accuracy, and precision for applications in drug discovery, drug repurposing, and drug safety.
  • San Diego Blood BankminorStrategic or Co-development Partner · 24 August 2016Multi-center collaboration for NHLBI Phase II SBIR on improving red blood cell transfusion through systems biology. The San Diego Blood Bank collaborated on testing novel additives to better preserve red blood cells for transfusion.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Sinopia Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Computational chemistry and materials science platform with a broader drug discovery offering including software, services, and internal pipeline. Larger and more diversified than Sinopia, but overlapping in the AI/ML-meets-pharma-discovery space.

Direct peers

  • BioAge Labs: AI/ML-driven biotech identifying drug targets from human aging biology data. Comparable approach to Sinopia in using proprietary omics datasets and machine learning for target identification and compound prioritization.
  • Exscientia: AI-native pharma combining precision design with automated experimentation to advance small molecule drug candidates. Comparable to Sinopia in marrying AI/ML with small-molecule discovery, though Exscientia has multiple clinical-stage assets and a much larger capital base.
  • Atomwise: AI-driven small molecule drug design using structure-based deep learning. Comparable to Sinopia's LEADS platform as an AI/ML drug discovery partner for pharma, with similar partnership-driven GTM motions.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutic targets. Directly comparable to Sinopia's LEADS platform in approach (data + ML for target ID) but at significantly larger scale and with clinical-stage assets.
  • Insitro: Machine learning-driven drug discovery platform integrating high-throughput biology and predictive models for therapeutic discovery. Closely aligned with Sinopia's LEADS philosophy of using ML on rich biological data to uncover novel targets.
  • Lantern Pharma: AI-driven precision oncology company using machine learning and multi-omics to identify and advance targeted therapies. Relevant given Sinopia's NCI-funded oncology work on cancer therapy resistance signatures.
  • Verge Genomics: AI/ML platform applying machine learning to human omics data for neuroscience drug discovery. Particularly relevant given Sinopia's focus on Parkinson's disease and the shared approach of using omics-derived insights to identify CNS targets.

Emerging players

  • Owkin: AI for biomedical research applying federated learning to multi-omics and clinical data for drug discovery and diagnostics. Comparable in the AI/omics-driven drug discovery space, particularly relevant to Sinopia's multi-omics integration approach.

Others

  • Metabolon: Specialty metabolomics services provider enabling biomarker discovery and multi-omics research. Adjacent to Sinopia — supplies the metabolomics data infrastructure that LEADS builds upon, and a potential data-generation partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights7 records

Customer concentration

Sinopia Biosciences social profiles

Digital presence

Sinopia Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sinopia Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

Sinopia Biosciences funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sinopia Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinopia Biosciences

What does Sinopia Biosciences do?

Sinopia Biosciences operates a proprietary drug-discovery platform called LEADS (LEarn And DiScover) that integrates high-throughput metabolomics data, AI/machine-learning foundation models engineered for omics, network analyses, and disease models to identify novel therapeutic targets and advance small-molecule drug candidates. Its most advanced program, SB-0110, is in clinical development for Parkinson's disease, with additional research programs spanning oral mucositis, oncology, rare blood disorders (platelet production), and rare metabolic diseases. The company monetizes this capability primarily through grant-funded research and milestone-bearing collaborations with biopharmaceutical partners such as Ono Pharmaceutical.

Is Sinopia Biosciences a public or private company?

Sinopia Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sinopia Biosciences founded?

Sinopia Biosciences was founded in 2014. It employs 1 to 10 people.

Where is Sinopia Biosciences based?

Sinopia Biosciences is headquartered in San Diego, United States, in the North America region.

How does Sinopia Biosciences make money?

Three revenue lines are on record. Grant Funding (NIH) is the primary driver. The others are strategic Partnerships and Collaborations and future Therapeutic Development.

Who are Sinopia Biosciences's main competitors?

Schrödinger is listed as a broad incumbent. Direct peers are BioAge Labs, Exscientia, Atomwise, Recursion Pharmaceuticals, Insitro, Lantern Pharma and Verge Genomics. Owkin is listed as an emerging player. Metabolon is listed as an others.

Does Sinopia Biosciences have an API?

No public API is recorded for Sinopia Biosciences.

What industry is Sinopia Biosciences in?

Sinopia Biosciences's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizSinopia Biosciences Awarded $2.5 Million NIH Grant to Advance AI Drug DiscoverySinopia Biosciences received a $2.5 million NIH SBIR Phase II grant to develop a metabolomics foundation model for drug discovery. The model aims to identify shared biological patterns across diverse datasets, supporting its LEADS platform. The company plans to expand the model and evaluate its ability to find new therapeutic targets.Technology NetworksParkinson's Drug Candidate Moves Toward Human TrialsSinopia Biosciences is advancing its drug candidate SB-0110 toward human clinical trials for Parkinson's disease following successful preclinical testing in rodent and nonhuman primate models. The combination of SB-0110 with levodopa demonstrated the ability to boost therapeutic benefits while significantly reducing dyskinesia side effects.BioengineeringDrug candidate may improve L-dopa effectiveness for Parkinson’s patientsA team led by Sinopia Biosciences has published preclinical evidence in Science Translational Medicine showing its lead compound SB-0110 enhanced levodopa's benefits while reducing dyskinetic side effects in rodent and non-human primate models of Parkinson's disease. The compound targets PKA-II, a brain signaling system implicated in dopamine and movement responses, and was derived from an older cardiac drug with prior safety experience outside the United States. Sinopia is completing toxicology studies for regulatory review and aims to begin first-in-human testing next year, with a projected six- to seven-year runway to patient availability if outcomes remain favorable.UC San Diego TodayThe Engineer Who Taught Cells to BehaveBernhard Palsson, a bioengineering professor at UC San Diego, has built a career developing computational models that make cellular behavior predictable and programmable, pioneering genome-scale metabolic models starting with E. coli in 2000 and extending to human metabolism. He has founded multiple biotechnology companies including Aastrom Biosciences (now Vericel Corporation), Genomatica, GT Life Sciences, and Sinopia Biosciences, and led the Novo Nordisk Foundation Center for Biosustainability in Denmark from 2010 to 2022, which spun out over 35 companies. His current work includes a $4.1 million DARPA subcontract to build a whole-cell "digital twin" model of E. coli to predict antibiotic resistance and inform patient care.BioSpaceSinopia Biosciences Awarded NCI Grant to Advance LEADS® Drug Discovery Platform for OncologySinopia Biosciences, a San Diego-based biotechnology company, has been awarded a research grant from the National Cancer Institute (NCI) to advance its LEADS® drug discovery platform for oncology applications. The grant will support the generation of large-scale datasets characterizing metabolic states of hundreds of cancer types and their therapeutic responses, combining high-throughput metabolomics with deep learning to identify metabolic signatures associated with anticancer therapy resistance. The research will build on Sinopia's existing metabolomics datasets and models to guide discovery of novel therapeutic targets and compounds.IndianpharmapostSinopia Biosciences scores NIH grant to supercharge AI-driven drug discoverySinopia Biosciences has received a research grant from the National Institute of General Medical Sciences (NIGMS), part of the NIH, to advance its LEADS AI-driven drug discovery platform. The platform analyzes hundreds of thousands of cellular features using system-level omics data to enable unbiased discovery of small-molecule therapeutics. Phase I funding will support the development of novel deep learning algorithms to expand metabolomic profiling across larger numbers of compounds and cell lines.BioSpaceSinopia Biosciences Awarded NIGMS Grant to Advance LEADS® Platform for Data-Driven Drug DiscoverySinopia Biosciences, a San Diego-based biotechnology company, has been awarded a Phase I research grant from the National Institute of General Medical Sciences (NIGMS), part of the NIH, to advance its LEADS® data-driven drug discovery platform. The grant will fund development of novel deep learning algorithms to expand coverage of chemical and biological space while reducing experimental burden in metabolomic characterization of small-molecule libraries. The platform has already been validated through identification of novel targets for multiple indications and advancement of a development candidate for Parkinson's disease.AijournSinopia Biosciences Awarded NIGMS Grant to Advance LEADS® Platform for Data-Driven Drug DiscoverySinopia Biosciences received a research grant from the National Institute of General Medical Sciences (NIGMS) to enhance its LEADS® drug discovery platform, which utilizes omics technologies and deep learning for data-driven drug development. The grant will fund the development of new algorithms and workflows to expand chemical and biological space coverage, with the goal of improving the efficiency of screening larger compound libraries.SinopiabioSinopia Biosciences Awarded NIGMS Grant to Advance LEADS® Platform for Data-Driven Drug Discovery — Sinopia BiosciencesSinopia Biosciences has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS) to further develop its proprietary LEADS® data-driven drug discovery platform. The funding will support Phase I development of deep learning algorithms to expand metabolomic characterization of small-molecule libraries and reduce experimental burden. This non-dilutive grant aims to optimize screening strategies for scaling across larger compound sets.SdbnSinopia Biosciences Awarded NIGMS Grant to Advance LEADS® Platform for Data-Driven Drug Discovery – San Diego Biotechnology NetworkSinopia Biosciences, a San Diego-based biotechnology company, has been awarded a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), to advance its proprietary LEADS® data-driven drug discovery platform. The grant will support the company's use of omics technologies for comprehensive characterization of cellular systems in drug discovery. No additional details about the grant amount or timeline were provided in the announcement.